Prucalopride Treatment Duration

Evidence-Based Treatment Duration

The American Gastroenterological Association and the American College of Gastroenterology note that clinical trials studied prucalopride for 4-24 weeks, with five pivotal 12-week randomized controlled trials forming the primary evidence base 1, 2
The FDA drug label explicitly states no time limit is provided for treatment duration, as recommended by the American Gastroenterological Association and the American College of Gastroenterology 1, 3

Assess response after 4 weeks of treatment to determine if the patient is benefiting, as suggested by the American Gastroenterological Association and the American College of Gastroenterology 1, 4
Most adverse events, such as headache, nausea, and abdominal pain, occur during the first week and typically resolve within a few days, according to the American Gastroenterological Association and the American College of Gastroenterology 4
Continue treatment as long as clinical benefit persists and the patient tolerates the medication, as recommended by the American Gastroenterological Association and the American College of Gastroenterology 1, 3

Evaluate efficacy at 4 weeks minimum based on increase in bowel movements per week and patient-reported satisfaction, as suggested by the American Gastroenterological Association and the American College of Gastroenterology 1, 4
Monitor for side effects that may lead to discontinuation, particularly diarrhea and gastrointestinal symptoms, with a relative risk of 3.00 vs placebo, as noted by the American Gastroenterological Association and the American College of Gastroenterology 1, 2

Do not discontinue prematurely before 4 weeks unless intolerable side effects occur, as initial gastrointestinal symptoms typically resolve, according to the American Gastroenterological Association and the American College of Gastroenterology 4
Do not assume treatment must be time-limited based on trial durations—the medication can be continued as long as clinically beneficial, as recommended by the American Gastroenterological Association and the American College of Gastroenterology 1, 3

The American Gastroenterological Association identified long-term use data as an evidence gap, noting that most trials studied 4-12 week durations despite chronic idiopathic constipation being a chronic condition 5

The American Gastroenterological Association identified a need for more long-term use data, although 18-24 month open-label data provide reassurance for chronic idiopathic constipation 5